Literature DB >> 2097710

Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia.

J J Schentag1.   

Abstract

In vitro, antibiotics are known to kill bacteria in predictable relationships to their broth concentrations. It was our hypothesis that serum concentration was an important determinant of the rate of bacterial eradication in patients. This contention was reinforced by animal studies, which have clearly demonstrated concentration-related antibacterial activity. The animal models rely on reduction of bacterial colony counts as an endpoint of effect, and demonstrate that colony count reductions are related to antibiotic dose and probably to serum concentration. We adapted these methods for use in intubated patients with Gram-negative pneumonia. Briefly, each patient had extensive staging of the pneumonic process, and the Gram-negative organism was isolated and its minimal inhibitory concentration (MIC) was determined. In each patient measurement of the antibiotic serum concentrations in the interval between two doses of the drug was also performed. The pharmacokinetic profile of the drug was then superimposed on the bacterial MIC, and we then derived the patients individual peak to MIC ratio, area above MIC, and time above MIC. Each of these pharmacokinetic parameters was then related to the time required to eradicate the bacterial pathogens in the patient. For beta-lactams and quinolones, time above MIC was the most predictive of bacterial eradication times. Clearly, these methods can be used to develop dosing strategies for patients, as well as to determine clinically relevant doses and dosing strategies in clinical trials. Further work is needed, however, to assess whether these concepts hold for other types of bacteria (such as Gram-positive) or apply as accurately to other infection sites in addition to pneumonia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2097710

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  17 in total

1.  Use of Modeling Techniques to Aid in Antibiotic Selection.

Authors:  Alexander A. Firsov; Stephen H. Zinner
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

2.  Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.

Authors:  M Kinzig; F Sörgel; B Brismar; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 3.  Role of beta-lactam agents in the treatment of community-acquired pneumonia.

Authors:  J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

Review 4.  Lung microdialysis--a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review).

Authors:  Markus Zeitlinger; Markus Müller; Christian Joukhadar
Journal:  AAPS J       Date:  2005-10-22       Impact factor: 4.009

Review 5.  The economic potential of dual individualisation methodologies.

Authors:  J A Paladino; G S Zimmer; J J Schentag
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

Review 6.  Quinolones in the treatment of lower respiratory tract infections in adult patients.

Authors:  C Carbon
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

Authors:  M Dan; F Poch; C Quassem; R Kitzes
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; S H Zinner; G Cornaglia; Y A Portnoy
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 9.  Continuous infusion of beta-lactam antibiotics.

Authors:  A P MacGowan; K E Bowker
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

Review 10.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.